Lithuanian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
anticonvulsants/insultas
Nuoroda įrašoma į mainų sritį
15 rezultatus
.DELTA.2-1,2,3-TRIAZOLINE ANTICONVULSANTS AND THEIR ACTIVE METABOLITE ANALOGUES, THE AMINOALKYLPYRIDINES, ARE EXCITATORY AMINO ACID ANTAGONISTS AND ANTIISCHEMIC AGENTS, USEFUL IN THE TREATMENT OF CEREBRAL ISCHEMIA RESULTING FROM STROKE
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
FIELD OF THE INVENTION
This invention relates to the drug potential of anticonvulsants in the treatment of stroke, particularly, several .DELTA..sup.2 -1,2,3-triazoline and aminoalkylpyridine (AAP) anticonvulsants that seem to work by impairing the excitatory amino acid (EAA) L-glutamate (L-Glu)
Arylalkyl-amines and -amides having anticonvulsant and neuroprotective properties
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
Compounds which possess anticonvulsant, antihypoxic or N-methyl-(d)-aspartate (NMDA) blocking properties are useful in the treatment and/or prevention of neurodegeneration in pathological conditions such as stroke, cerebral ischaemia, cerebral palsy, hypoglycaemia, epilepsy, Alzheimer's disease,
Arylalkyl-amines and -amides having anticonvulsant and neuroprotective properties
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
This invention relates to pharmaceutical compounds, some of which are novel, and to their anticonvulsant, sedative and neuroprotective properties.
Compounds which possess anticonvulsant, antihypoxic or N-methyl-(d)-aspartate (NMDA) blocking properties are useful in the treatment and/or prevention of
Anticonvulsant compound
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is the U.S. national phase under 35 U.S.C. .sctn. 371 of PCT International Application No. PCT/GB2015/052624, which has an international filing date of Sep. 10, 2015 and designated the United States of America, which application claims benefit
Valproyltaurinamide derivatives as anticonvulsant amd CNS active agents
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
FIELD OF THE INVENTION
The invention relates to new derivatives of valproic acid and taurine, a method for their preparation and use for thereof for the treatment of epilepsy, neurological, affective and psychotic disorders as well as for the treatment of pain and migraine.
BACKGROUND OF THE
Arylalkyl-amines having anticonvulsant and neuroprotective properties
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
This invention relates to pharmaceutical compounds, some of which are novel, and to their anticonvulsant, sedative and neuroprotective properties.
Compounds which possess anticonvulsant, antihypoxic or N-methyl-(d)-aspartate (NMDA) blocking properties are useful in the treatment and/or prevention of
Arylalkyl-amines having anticonvulsant and neuroprotective properties
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
This invention relates to pharmaceutical compounds, some of which are novel, and to their anticonvulsant, sedative and neuroprotective properties.
Compounds which possess anticonvulsant, antihypoxic or N-methyl-(d)-aspartate (NMDA) blocking properties are useful in the treatment and/or prevention of
Use of conantokins
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
BACKGROUND OF THE INVENTION
The invention relates to the use of relatively short peptides, about 10-30 residues in length, which are naturally available in minute amounts in the venom of the cone snails or analogous to the naturally available peptides, and which include preferably one to two or more
Use of conantokins
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
BACKGROUND OF THE INVENTION
The invention relates to the use of relatively short peptides, about 10-30 residues in length, which are naturally available in minute amounts in the venom of the cone snails or analogous to the naturaly available peptides, and which include preferably one to two or more
Tricyclic monosaccharide derivatives useful in treating acute ischemia-induced neurodegeneration
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
BACKGROUND OF THE INVENTION
Compounds of formula I: ##STR2##
are structurally novel anticonvulsants (Maryanoff, B. E., Costanzo, M. J., Nortey, S. O., Greco, M. N., Shank, R. P., Schupsky, J. J., Ortegon, M. E., and Vaught, J. L. J. Med. Chem. 1998, 41, 1315-1343), found to possess anticonvulsant
Quinolinic sulfide derivatives acting as NMDA receptor antagonists and process for preparation thereof
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
FIELD OF THE INVENTION
The present invention relates to therapeutically active quinolinic sulfide derivatives acting as potent and specific antagonists of excitatory amino acids, to a process for preparation and to their use in treatment in neurological disorders.
Particularly, the compounds
Neurotherapeutic azole compounds
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
FIELD OF THE INVENTION
The present invention is directed to neurotherapeutic azole compounds containing a carbamoyl group which are useful as anticonvulsant agents.
DESCRIPTION OF THE PRIOR ART
Many reports have disclosed that arylalkyl azole compounds are effectively used as anticonvulsant,
Neuroprotection and neuroegenisis by administering cyclic prolyl glycine
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
BACKGROUND OF THE INVENTION
NMDA AMPA Receptors
Excessive excitation by neurotransmitters can cause the degeneration and death of neurons. It is believed that this degeneration is in part mediated by the excitotoxic actions of the excitotoxic amino acids (EAA) glutamate and aspartate at the
Compounds advantageous in the treatment of central nervous system diseases and disorders
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
BACKGROUND OF THE INVENTION
1. The Field of the Invention
The present invention relates to novel compounds showing activity in the central nervous systems (CNS). More specifically, the present invention relates to novel compounds with anticonvulsant activity that exhibit increased/improved
Compounds advantageous in the treatment of central nervous system diseases and disorders
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
BACKGROUND OF THE INVENTION
1. The Field of the Invention
The present invention relates to novel compounds showing activity in the central nervous systems (CNS) of experimental animals. More specifically, the present invention relates to novel compounds with anticonvulsant activity that exhibit
Išsamiausia vaistinių žolelių duomenų bazė, paremta mokslu
- Dirba 55 kalbomis
- Žolelių gydymas, paremtas mokslu
- Vaistažolių atpažinimas pagal vaizdą
- Interaktyvus GPS žemėlapis - pažymėkite vaistažoles vietoje (netrukus)
- Skaitykite mokslines publikacijas, susijusias su jūsų paieška
- Ieškokite vaistinių žolelių pagal jų poveikį
- Susitvarkykite savo interesus ir sekite naujienas, klinikinius tyrimus ir patentus
Įveskite simptomą ar ligą ir perskaitykite apie žoleles, kurios gali padėti, įveskite žolę ir pamatykite ligas bei simptomus, nuo kurių ji naudojama.
* Visa informacija pagrįsta paskelbtais moksliniais tyrimais
